ADMA Biologics, Inc. (ADMA) — Analysis Summary
ADMA Biologics, Inc. (ADMA) has a market cap of $1.85B with year-over-year revenue growth of +19.6%. Net margin stands at 28.8%. The stock trades at a P/E ratio of 11.2.
Key Takeaways
- Revenue changed +19.6% year-over-year
- Net margin of 28.8%
- P/E ratio of 11.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, ADMA posted revenue growth of +19.6% and trades at a P/E of 11.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.